<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734327</url>
  </required_header>
  <id_info>
    <org_study_id>SMC2021001</org_study_id>
    <nct_id>NCT04734327</nct_id>
  </id_info>
  <brief_title>Orthokine Therapy in Lumbar Degenerative Disease</brief_title>
  <acronym>OLDDD</acronym>
  <official_title>Orthokine Therapy in Lumbar Degenerative Disease: Does the Route of Administration Really Matter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutherland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutherland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is the comparison of the effectiveness of two methods of Orthokine&#xD;
      administration (periradicular or epidural) in lumbar degenerative disc disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Lumbar Degenerative Disc Disease (LDDD) is a serious, global health problem for&#xD;
      patients from the third decade of life. It is assumed that 75-85% of the population suffer&#xD;
      from pain in the lumbar spine at least once during their lifetime (vital morbidity), and 3-5%&#xD;
      of the population suffer from root-type pain.&#xD;
&#xD;
      The annual prevalence of the spine complaints in the United States alone ranges from 15 to&#xD;
      20%, and in Europe it ranges from 25 to 45%.&#xD;
&#xD;
      In addition to the immeasurable losses associated with impaired patient activity and a&#xD;
      significant reduction in the quality of their life, LBP is the greatest burden for the world&#xD;
      economy, measured by the years lived with disability (YLD) index due to a significant&#xD;
      reduction in the productivity and professional ability of patients affected by LBP.&#xD;
&#xD;
      AIM: Assessment of the effectiveness of symptomatic treatment of Lumbar Degenerative Disc&#xD;
      Disease (LDDD) with the autologous Orthokine serum, comparison of two methods of its&#xD;
      application - epidural or periradicular.&#xD;
&#xD;
      DESIGN: Randomized prospective trial without blinding SETTING: Open study for outpatients,&#xD;
      single center study POPULATION: local population METHODS: Two groups of patients (A, B) with&#xD;
      confirmed LDDD by MRI, without gender or age limitation, meeting the health conditions&#xD;
      according to the inclusion and exclusion criteria. There will be 50 people in each group (100&#xD;
      people in total).&#xD;
&#xD;
      Group A - therapy with Orthokine serum - a total of 4 injections of 2 doses at weekly&#xD;
      intervals (4 doses of 4 ml of serum in total), injections will be performed into the epidural&#xD;
      space from an interlaminar access under ultrasound guidance by the same operator.&#xD;
&#xD;
      Group B - therapy with Orthokine serum - a total of 4 injections of 1 or 2 doses depending on&#xD;
      the number of levels occupied at weekly intervals (a total of 4 doses of 4 ml of serum),&#xD;
      injections will be performed periradicular (transforaminal) under ultrasound guidance by the&#xD;
      same operator.&#xD;
&#xD;
      Assessment tools: Numeric Rating Scale NRS (0-10), Oswestry Disability Index questionnaire,&#xD;
      Roland Morris questionnaire, EQ-5D-5L questionnaire Control points W0 - before the therapy,&#xD;
      W1 - 1 month after the last dose of serum W2 - 3 months after the last dose of serum W3 - 6&#xD;
      months after the last serum dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EQ-5D-5L index from baseline to 24 weeks</measure>
    <time_frame>Time Frame: Change from baseline to 24 weeks</time_frame>
    <description>EQ-5D-5L index estimated from EQ-5D-5L descriptive system based on Polish directly measured value set. Minimum: -0.590; Maximum: 1.0; More points means better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oswestry Disability Index from baseline to 24 weeks</measure>
    <time_frame>Time Frame: Change from baseline to 24 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Roland Morris Questionnaire score from baseline to 24 weeks</measure>
    <time_frame>Time Frame: Change from baseline to 24 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 24 (the worst score).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain according to Numeric Rating Scale (NRS) from baseline to 4 weeks</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>0 (no pain) - 10 points (the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain according to Numeric Rating Scale (NRS) from baseline to 12 weeks</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>0 (no pain) - 10 points (the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain according to Numeric Rating Scale (NRS) from baseline to 24 weeks</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>0 (no pain) - 10 points (the worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D-5L index from baseline to 4 week</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>EQ-5D-5L index estimated from EQ-5D-5L descriptive system based on Polish directly measured value set. Minimum: -0.590; Maximum: 1.0; More points means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D-5L index from baseline to 12 week</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>EQ-5D-5L index estimated from EQ-5D-5L descriptive system based on Polish directly measured value set. Minimum: -0.590; Maximum: 1.0; More points means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oswestry Disability Index from baseline to 4 weeks</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oswestry Disability Index from baseline to 12 weeks</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Roland Morris Questionnaire score from baseline to 4 weeks</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 24 (the worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Roland Morris Questionnaire score from baseline to 12 weeks</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 24 (the worst score).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Lumbar Region</condition>
  <arm_group>
    <arm_group_label>Orthokine periradicular injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guided injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthokine epidural injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound guided injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Orthokine periradicular injection</intervention_name>
    <description>Ultrasound guided injections</description>
    <arm_group_label>Orthokine periradicular injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Orthokine epidural injection</intervention_name>
    <description>Ultrasound guided injections</description>
    <arm_group_label>Orthokine epidural injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical symptoms of LDDD in the lumbar region&#xD;
&#xD;
          2. LDDD confirmed by MRI&#xD;
&#xD;
          3. No contraindications to injections (hemorrhagic diathesis, anticoagulants, skin&#xD;
             lesions)&#xD;
&#xD;
          4. An adult consenting to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of severe neurological deficits requiring surgery&#xD;
&#xD;
          2. Discopathy of other origin - traumatic, spondylolisthesis, cancer, infection,&#xD;
             inflammatory systemic diseases&#xD;
&#xD;
          3. Previous surgical treatment in the lumbar spine&#xD;
&#xD;
          4. Mental state that prevents cooperation during injection&#xD;
&#xD;
          5. Contraindications for injection (hemorrhagic diathesis, anticoagulants, skin lesions)&#xD;
&#xD;
        5. Lack of consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Godek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutherland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sutherland Medical Center</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>04-036</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Godek, MD</last_name>
      <phone>+48 22 67 360 43</phone>
      <email>piotrgodek.smc@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sutherland Medical Center</investigator_affiliation>
    <investigator_full_name>Piotr Godek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>degenerative disc disease</keyword>
  <keyword>lumbar spine</keyword>
  <keyword>conservative treatment</keyword>
  <keyword>Orthokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

